针 对 COVID 19 疫情，当前决胜的关键，在于如何提高抗体流行率，以达到群体免疫，最终解除疫情这个目的。因此强烈建议，针对 COVID 19 的康复患者是否具有传染性，给出一个权威的实验结论。也就是说，应该检测那些尚未具有抗体的易受感染者，以验证他们在与这些已具有抗体的康复患者密切接触之后，是否会产生抗体？当然 这是一个可行的实验。 这意味着，应该有一种具有传染性的新冠病毒（ SARS CoV 2 ）疫苗一直 存在于我们身边，而且是唾手可得。 此外还指出，病毒与人体免疫系统对立且能共处的平衡状态，是它们生存和增殖所面临的环境，而传染性是必要条件。 正是在这样的环境下，那些原始病毒的后代才有可能得到人体免疫系统的改良，从而进化成 IgG 抗体的主体。 鉴于目前已确认无症状感染者可以传播病毒，于是推断，具有传染性的新冠病毒减毒活疫苗也一定存在。 (In allusion to the COVID-19 epidemic situation, the current key point to win the decisive victory is on how to improve the antibody prevalence, so as to achieve herd immunity and eventually eliminate the epidemic situation. Therefore, it is strongly recommended that an authoritative experimental conclusion should be given on whether the recovered patients with COVID-19 are infectivity or not. That is to say, those susceptible people who have not yet had the antibodies should be tested, in order to verify whether they would produce antibodies after close contact with the recovered patients who have had the antibodies. Of course, this is a feasible experiment. The implication that there should be a type of infectious vaccines against SARS-CoV-2, which is always around us and well within reach. In addition, it is pointed out that the state of balance where the viruses and the human immune system are opposed and can coexist is the environment they face for survival and proliferation, while the infectivity is the necessary condition. It is under such environment that the progenies of those original viruses would be just possible to be improved by human immune system, thereby evolve into the main part of the IgG antibodies. Since asymptomatic infected persons are now confirmed to transmit the viruses, so it is inferred that the Infectious Attenuated Live Vaccine against SARS-CoV-2 must be there too. )